Member Info for Fruitsnveg

Are Synairgen attending or presenting at this?

Https://www.independent.co.uk/news/health/flu-covid-vaccines-brought-forward-ba286-variant-b2401989.html

To your question TP, I cannot say with any certainty but only guess as you have done. What leads me to expect that movement here might take less than a year, is the fact that hitherto there was less data on the groups to target, stratification, refining of protocols based on analysis of past failure, the phenotype work in general, and collaboration on Universal - my expectation is that all of these will in some way inform the Synairgen team more than in the previous P2. Couple that with the early delivery of data on Universal in January - something that was not expected according to Prof Wilko. If there is indeed interest from BP conditional on further data, then my expectation is that the first sign of early data showing promise could well result in a collaborative pathway forward, with little delay. If you are interested the commercial potential of an enterprise, you don't wait for it to present it's wares to your competitors (and risk getting into a bidding war), you quietly make a mutually acceptable offer and you take it forward yourself. They won't be waiting for published results. If new trial data shows stronger commercial viability which triggers a move from a 3rd party, this will fly IMHO. Worth noting that opposite is also true.

Agree it's a good article bringing new insight and cross-referencing latest data (some from June/July 2023 so very current). What it doesn't mention at all is the timeline for clinical trials -I see you expect this to take a year TP, is this based on something the company stated?

Only one?

Many trusts in the NHS have been reporting an 80% increase in hospitalised Covid patients in the past 4 weeks. As we know from pervious waves, small numbers can explode under the right conditions. Anything that drives people indoors en masse to transmit the virus will speed it's reach and eventually it's evolution. While Rome has been burning and Sunak has been twiddling the hand-rolled edges of his Hermes hankies, the experts have again started to call for the return of masks and other steps to halt the march of 2 newest variants. You won't need to wait until January for the -1 temp dip to see patient numbers increase further. All it takes is a wet week huddled indoors, a mass return to schools, or a couple of sold out Swifty concerts.

Maybe it never worked very well for you Sakura and that let's not forget that was 40+ years ago when scientific methods were at best rudimentary in comparison to today's baffling technological and clinical advances. All scientists are not equally rigorous, successful or motivated in their endeavours, it happens. AZ, and more recently Janssen on the other hand, they seem to think it IS worthy of investigation. Which is funny, right? Maybe you know more than these 2 pharma giants?

"Nationally, the number of hospital patients with Covid-19 has increased by 81% in the last four weeks."

Can't find the original data but if you google the above, it seems to be reported by a number of NHS trusts in the past 24 hrs.

I would expect this will benefit the timely generation of data on the UNIVERSAL study.

The output of the Universal trial will be "a longitudinal clinical database of respiratory viral infections in hospitalised patients to inform the development of potential antivirals to treat severe viral lung infections caused by seasonal viruses and emerging viral threats". How they arrive at populating that database doesn't occupy too much of my brain, my focus on the findings of the study, how that enhances the development path of SNG001 specifically.

Perhaps you should read my "cut and paste job" of the study aims so you understand it properly, or better still read the original text yourself. You seem to have difficulty understanding that SNG001 patients won't be treated with SNG001 during the trial. Confirmatory signals (of what you are referring to who knows?) are not part of the study. To recap, Universal aims to identify the incidence of different respiratory viruses in a population of patients admitted to hospital with suspected respiratory viral infections to determine different factors which may affect how disease progresses as well as recovery time and length of stay. Secondary to this, the study aims to understand time to recovery for different viruses as well as patient cost estimate.

That's it. No signals, no dilution, just observational data.

That is incorrect. There is absolutely no Universal "signal" expected.

The trial record states .... "Nose and throat swab will be collected and a point of care to test to determine if the participant has a respiratory viral infection will be carried out. Only those who test positive for a respiratory viral infection will go on to stage 2 of the study, although all participants who consent will have baseline data recorded. In stage 2, further nose and throat swabs and blood samples will be collected on days 1, 3 and 7 of enrolment. As well as completing questionnaires about how they are feeling while in hospital, participants will complete questionnaires following discharge from hospital at pre-specified time points up to 26 weeks later. This study is an observational study, so participants will receive no treatment different from standard of care, but the study will help researchers to better understand the course of respiratory viral infections. This may help aid the treatment of patients in the future as well as the development of new treatments. "

One could speculate too that in co-infections recombination remains feasible. Mitigation measures and testing for both MERS-CoV and SARS-CoV-2 in ME countries has probably decreased over the past 2 years when the NIH published a paper on that exact threat, but no doubt it remains on the radar. Particularly following the recently reported case of Mers (of unknown origin) in Abu Dhabi. It seems these sneaky viruses never go, they just hide in plain sight.

Not sure what dosing in Sept 2022 you are referring to Doc.Dan, UNIVERSAL is an observational study, not an interventional one.

Any Tom, Dick or Harry can approach any company with any self-serving ‘funding’ ideas. Few are ever in the commercial interests of other shareholders.

"they'll have to take on a major partner to do anything substantial"

Not really. They already have the interest of what we can assume is a major player, one who has requested additional data based on small trials in H2. The smaller the trials the quicker the read-outs. And certainly, any BP worth their salt, will be leaning into their due diligence files rather than waiting for any official read-outs. I don't see this getting overly complicated and certainly p3 is far from my mind now. "Trial-let" data will drive any deal, and those small agile trials will drive the data. I'm looking at a major SP-enhancing catalyst within the next 12 months; I see no reason currently why that cannot be achieved.

Helen Gearing is an SVP and Brooke Clarke was an SVP. Why would they get options?

"And there isn't something major in the offing anyway".

Says who?

It does, doesn't it.

#rebuffed.

Thanks for that voting info / link TommyD_19, all works as stated and made the process quick and easy.

I echo Doc.Dan's best wishes - sorry to hear of your diagnosis and I hope your treatment is going well.

Thanks for that clarification Tommy_D19. Not "at leisure" as misinformed Snackman would have us believe.

Dependent instead on actual performance criteria. Got it.